(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 June 2013 (06.06.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/082559 A1

(51) International Patent Classification:
A61K 31/555 (2006.01)

(21) International Application Number:
PCT/US2012/067484

(22) International Filing Date:
30 November 2012 (30.11.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/565,842 1 December 2011 (01.12.2011) US

(71) Applicant: **INFACARE PHARMACEUTICAL CORPORATION** [US/US]; 8 Neshaminy Interplex, Suite 221, Trevose, PA 19053 (US).

(72) Inventors: **TULLOCH, Simon, J.**; 233 Kent Oaks Way, Gaithersburg, MD 20878 (US). **WASIEWSKI, Warren, W.**; 2051 Waterford Drive, Lancaster, PA 17601-5456 (US).

(74) Agents: **PATANE, Michael, A.** et al.; Pepper Hamilton LLP, Suite 5000, 500 Grant Street, Pittsburgh, PA 15219-2507 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: METHODS FOR TREATING HYPERBILIRUBINEMIA WITH STANNSOPORFIN

(57) Abstract: Some embodiments relate to methods of treating hyperbilirubinemia comprising administrating a therapeutic amount of a metalloporphyrin to an infant. Administration may occur when the infant's measured total serum bilirubin levels are at or below about t level suggested by the AAP nomogram for initiating phototherapy, when the infant's measured total serum bilirubin levels are at about the level suggested for initiating phototherapy in an infant, or when the infant's measured total serum bilirubin levels are at about the level suggested for initiating phototherapy. Administration may occur without regard to the total serum bilirubin level of the infant. In some embodiments, administration of the metalloporphyrin does not cause QT prolongation.




FIGURE 1

WO 2013/082559 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*